Open access
Open access
Powered by Google Translator Translator

General Interest

RCT: Lack of significant effect of Paxlovid (nirmatrelvir–ritonavir) on symptom alleviation in Covid-19

26 Apr, 2024 | 11:49h | UTC

Study Design and Population:

This phase 2–3 randomized clinical trial investigated the efficacy of nirmatrelvir in combination with ritonavir for treating mild-to-moderate Covid-19 in adults. Participants, both vaccinated and unvaccinated, were enrolled based on their risk factors for severe Covid-19. The study included 1296 adults who had confirmed Covid-19 with symptom onset within the past 5 days. They were randomly assigned to receive either nirmatrelvir–ritonavir or placebo every 12 hours for 5 days.

 

Main Findings:

The primary endpoint was the time to sustained alleviation of all targeted Covid-19 signs and symptoms. Results showed that the median time to alleviation was 12 days for the treatment group and 13 days for the placebo group, a difference that was not statistically significant (P=0.60). Hospitalizations and deaths were slightly lower in the treatment group (0.8%) compared to the placebo group (1.6%), but this difference was also not statistically significant. Adverse events were similar across both groups, with dysgeusia and diarrhea being the most common in the treatment group.

 

Implications for Practice:

The findings indicate that nirmatrelvir–ritonavir treatment does not significantly reduce the time to symptom alleviation for Covid-19 compared to placebo among vaccinated or unvaccinated adults. These results suggest that further research is needed to explore the potential benefits of this treatment in specific subpopulations or in combination with other interventions.

 

Reference (free full-text):

Reference: Hammond J. et al. (2024). Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. N Engl J Med, 390(13), 1186-1195. DOI: 10.1056/NEJMoa2309003


Systematic Analysis: Global Burden and Trends of Nervous System Disorders, 1990–2021

21 Mar, 2024 | 11:10h | UTC

Study Design and Population

This study, a systematic analysis conducted by the Global Burden of Disease Study 2021, aimed to estimate the global, regional, and national health loss attributable to 37 unique nervous system conditions from 1990 to 2021. The researchers estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) across 204 countries. The analysis included morbidity and deaths directly resulting from damage to the central or peripheral nervous system, as well as neurological health loss from conditions where nervous system morbidity is a secondary outcome.

Main Findings

The collective global burden of these nervous system conditions emerged as the leading cause of DALYs in 2021, affecting approximately 3.40 billion individuals (43.1% of the global population) and resulting in 443 million DALYs. Although global DALY counts for these conditions increased by 18.2% from 1990 to 2021, there was a notable decrease in the age-standardised rates of deaths and DALYs by 33.6% and 27.0%, respectively. The conditions contributing most significantly to the age-standardised DALYs were stroke, neonatal encephalopathy, migraine, and Alzheimer’s disease among others.

Implications for Practice

This analysis underscores the critical need for effective prevention, treatment, and rehabilitation strategies for nervous system disorders, which now lead the global disease burden. Highlighting an 18.2% increase in DALY counts over the study period, it calls for heightened public health attention and resource allocation towards these conditions. The findings support the prioritization of nervous system health on the global health agenda and stress the importance of further research into modifiable risk factors and equitable access to care.

Reference

GBD 2021 Nervous System Disorders Collaborators (2024). Systematic Analysis: Global Burden and Trends of Nervous System Disorders, 1990–2021. The Lancet Neurology, Volume(issue), Pages. DOI: https://doi.org/10.1016/S1474-4422(24)00038-3. Access the study here: Link


Meta-Analysis: Efficacy of exercise modalities in major depressive disorder treatment

20 Mar, 2024 | 17:54h | UTC

Study Design and Population: This article presents a systematic review and network meta-analysis of randomized controlled trials to assess the optimal dose and modality of exercise for treating major depressive disorder, comparing its effects to psychotherapy, antidepressants, and control conditions such as usual care or placebo. The review included 218 unique studies encompassing 495 arms with a total of 14,170 participants who met the clinical cutoffs for major depression.

Main Findings: The findings revealed moderate reductions in depression symptoms for several exercise modalities when compared to active controls. Notably, walking or jogging, yoga, and strength training demonstrated the most significant effects. The effectiveness of exercise was found to be proportional to the intensity of the activity prescribed. Among these, yoga and strength training were identified as the most acceptable modalities for participants. However, the overall confidence in these results is low due to the high risk of bias in the included studies, with only one study meeting the criteria for a low risk of bias.

Implications for Practice: The study concludes that exercise, particularly walking or jogging, yoga, and strength training at sufficient intensities, can be an effective treatment for major depressive disorder. These modalities could be recommended alongside traditional treatments such as psychotherapy and antidepressants. Future research should focus on blinding participants and staff to mitigate expectancy effects and improve the reliability of findings. The inclusivity of exercise as a core treatment for depression could significantly impact treatment strategies and patient outcomes.

Reference: Noetel, M., et al. (2024). Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ, 384, e075847. DOI: https://doi.org/10.1136/bmj-2023-075847. Access the study here: [Link]


Perspective | Clinicians debate the usefulness of NAFLD name change

11 Aug, 2023 | 15:39h | UTC

Clinicians debate the usefulness of NAFLD name change – MDedge

Original article: From NAFLD to MASLD | New consensus changes fatty liver disease terminology to avoid stigmatization

 


Study | The high financial and human cost of quality metric reporting in hospitals

11 Aug, 2023 | 15:36h | UTC

The Volume and Cost of Quality Metric Reporting – JAMA (link to abstract – $ for full-text)

Author Interview: The Costs of Quality Reporting – JAMA

Commentaries:

The Cost of “Quality” – Emergency Medicine Literature of Note

How John Hopkins spent $5m and 108,478 hours on quality reporting in one year – HealthLeaders

The cost of quality metric reporting – Becker’s Hospital Review

 


[News Release] RCT | Semaglutide 2.4 mg reduces cardiovascular risk by 20% in adults with CVD & obesity

9 Aug, 2023 | 15:40h | UTC

Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial – Novo Nordisk

Commentaries:

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity – TCTMD

Expert reaction to Novo Nordisk press release announcing the headline results from their SELECT cardiovascular outcomes semaglutide trial – Science Media Centre

Related: Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity – Journal of the American Heart Association

 


Perspective | Creation and adoption of large language models in medicine

9 Aug, 2023 | 15:38h | UTC

Creation and Adoption of Large Language Models in Medicine – JAMA (free for a limited period)

Commentary: Rethinking large language models in medicine – Stanford Medicine

 


Perspective | An AI-enhanced electronic health record could boost primary care productivity

9 Aug, 2023 | 15:36h | UTC

An AI-Enhanced Electronic Health Record Could Boost Primary Care Productivity – JAMA (free for a limited period)

 


Perspective | Large language models answer medical questions accurately, but can’t match clinicians’ knowledge

9 Aug, 2023 | 15:35h | UTC

Large Language Models Answer Medical Questions Accurately, but Can’t Match Clinicians’ Knowledge – JAMA (free for a limited period)

 


Perspective | Artificial-intelligence search engines wrangle academic literature

9 Aug, 2023 | 15:33h | UTC

Artificial-intelligence search engines wrangle academic literature – Nature

 


Research Letter | GPT-3.5 and GPT-4 show low accuracy in citing journal articles

9 Aug, 2023 | 15:31h | UTC

Accuracy of Chatbots in Citing Journal Articles – JAMA Network Open

 

Commentary on Twitter

 


Survey | The manifold costs of being a non-native English speaker in science

7 Aug, 2023 | 15:00h | UTC

The manifold costs of being a non-native English speaker in science – PLOS Biology

Commentary from the author: Non-native English speaking scientists work much harder just to keep up, global research reveals – The Conversation

News Releases:

The cost of being a non-native English speaker in science – PLOS

Science language barrier could cost countless careers – University of Queensland

 

Commentary on Twitter

 


RCT | Mammography screening with AI reduces workload by 44.3% without loss in detection efficacy

4 Aug, 2023 | 12:13h | UTC

Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study – The Lancet Oncology (link to abstract – $ for full-text)

News Release: First randomized trial finds AI-supported mammography screening is safe and almost halves radiologist workload – Lancet

Commentaries:

Large Mammography Study Shows Significant Benefits with AI-Aided Screening – Diagnostic Imaging

Expert reaction to interim safety analysis of randomised trial on AI-supported mammography screening – Science Media Centre

 


Evidence Review | AA and other 12-step programs outperform CBT for alcohol use disorder

2 Aug, 2023 | 14:05h | UTC

Alcohol dependence: evidence and experience on 12 steps to recovery – Evidently Cochrane

Original study: Alcoholics Anonymous and other 12‐step programs for alcohol use disorder – Cochrane Library

 


UNESCO calls for global ban on smartphones in schools

28 Jul, 2023 | 14:26h | UTC

Report: Technology in education – UNESCO

News Releases:

UNESCO calls for global ban on smartphones in schools – UN News

Smartphones in school? Only when they clearly support learning – UNESCO

Commentary: ‘Put learners first’: Unesco calls for global ban on smartphones in schools – The Guardian

 


Study | Only 11% of sports supplements listing botanical ingredients accurately declare contents, 12% contain FDA-prohibited stimulants

28 Jul, 2023 | 14:21h | UTC

Presence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements – JAMA Network Open

Commentaries:

Ensuring the Safety and Value of Supplements – JAMA Network Open

Sports Supplements Can Be Contaminated with Botanical Stimulants and Anabolic Agents – NEJM Journal Watch

 


BMJ Investigation | Medical royal colleges receive millions from drug and medical devices companies

28 Jul, 2023 | 14:19h | UTC

Medical royal colleges receive millions from drug and medical devices companies – The BMJ

News Release: Medical royal colleges receive millions from drug/medical device companies – BMJ Newsroom

 

Commentary on Twitter

 


Study | New deep learning model effectively detects type 2 diabetes from chest X-rays

28 Jul, 2023 | 14:15h | UTC

Opportunistic detection of type 2 diabetes using deep learning from frontal chest radiographs – Nature Communications

 

Commentary on Twitter

 


Cohort Study | BMI of 25.0–29.9 not linked with higher mortality in 21st century U.S. adults

25 Jul, 2023 | 13:58h | UTC

Body mass index and all-cause mortality in a 21st century U.S. population: A National Health Interview Survey analysis – PLOS One

News Release: No increase in mortality for most overweight people, study finds – PLOS

Commentary: Expert reaction to study looking at BMI and all-cause mortality – Science Media Centre

 


Perspective | Digital health for aging populations

24 Jul, 2023 | 13:13h | UTC

Digital health for aging populations – Nature Medicine (if the link is paywalled, try this one)

 


Perspective | Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed?

24 Jul, 2023 | 13:12h | UTC

Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed? – Nature

Related: Dozens of recent clinical trials may contain wrong or falsified data (free study by John Carlisle)

 

Commentary on Twitter

 


Correspondence | Potential “healthy vaccinee bias” in a study of BNT162b2 vaccine against Covid-19

21 Jul, 2023 | 13:43h | UTC

Potential “Healthy Vaccinee Bias” in a Study of BNT162b2 Vaccine against Covid-19 – New England Journal of Medicine

 

Commentary from the author on Twitter (thread – click for more)

 


Study | Large language models show potential for medical question answering capabilities

20 Jul, 2023 | 11:12h | UTC

Large language models encode clinical knowledge – Nature

News Release: Benchmarking AI’s ability to answer medical questions – Nature Publishing Group

Commentary: Expert reaction to study presenting Med-PaLM, a large language model (LLM) for answering medical questions, and a benchmark for assessing how well LLMs can answer medical questions – Science Media Centre

 


Changes to breast structure and function across a woman’s lifespan: implications for managing and modeling female breast injuries

19 Jul, 2023 | 14:29h | UTC

Changes to breast structure and function across a woman’s lifespan: Implications for managing and modeling female breast injuries – Clinical Biomechanics

Commentary: Breast injuries are common for female athletes. Here’s why better awareness and reporting are needed – The Conversation

 


Survey Study | ChatGPT’s performance in simulated patient-provider interactions

19 Jul, 2023 | 14:28h | UTC

Putting ChatGPT’s Medical Advice to the (Turing) Test: Survey Study – JMIR Medical Education

News Release: ChatGPT’s responses to healthcare-related queries ‘nearly indistinguishable’ from those provided by humans – NYU Tandon School of Engineering

Related: ChatGPT’s responses to patient questions rated higher for quality and empathy than physicians

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.